Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic.
about
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysisEpithelial-mesenchymal transition in cells expanded in vitro from lineage-traced adult human pancreatic beta cellsRoles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer MetastasisTransient receptor potential channel C5 in cancer chemoresistanceMitochondrial ROS and cancer drug resistance: Implications for therapyImplications of the Hybrid Epithelial/Mesenchymal Phenotype in MetastasisPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceThe genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateAurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosisNeuraminidase-1: a novel therapeutic target in multistage tumorigenesisΔNp63α and microRNAs: leveraging the epithelial-mesenchymal transitionAKT-ions with a TWIST between EMT and METThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisCharacterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinomaThe Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancerIdentification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMTGenome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancerEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerAn in vitro correlation of mechanical forces and metastatic capacity.Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors.Induction of Slug by Chronic Exposure to Single-Walled Carbon Nanotubes Promotes Tumor Formation and Metastasis.Non-thermal atmospheric pressure plasma inhibits thyroid papillary cancer cell invasion via cytoskeletal modulation, altered MMP-2/-9/uPA activity.Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma.TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.Novel tools for prostate cancer prognosis, diagnosis, and follow-upSerum depletion induces changes in protein expression in the trophoblast-derived cell line HTR-8/SVneo.Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signalingGlucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Detection of differentially expressed basal cell proteins by mass spectrometryTransglutaminase regulation of cell function.USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4.HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionMTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cellsLARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis.AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis.Targeting Notch signaling pathway to overcome drug resistance for cancer therapyTargeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.
P2860
Q21136141-2FBB0E26-EA02-45D8-A3FD-3F4410E76C94Q21562390-DED3580E-BCE1-4F87-9DED-8B5396B9F35DQ26745561-B8D37F19-B7C6-4892-A86B-F141E68DF3FEQ26776483-15890EBE-2C9E-445C-88AA-FE4F540B2F73Q26798106-5A6D3AE9-98FE-49DF-9D65-321EB850329CQ26799987-3715F058-A597-4735-9249-691B65745B97Q26866517-9E146024-01C8-4F62-B447-22130B39B9E6Q27003050-B3D42C04-A0CD-4773-99B4-4BC8569BC1B1Q27853047-551F9CEF-84D5-4726-8243-63FF6647E6E6Q28066130-5A3C27F2-D64E-4168-AD3B-41016D4B311DQ28077508-A929C211-0C55-4EFC-8D0E-31729680A90DQ28078987-AE092988-D7D8-46BE-BAD4-7F10D3F4C54FQ28388257-87056FD5-12F2-4367-8450-7811F6909553Q28485385-57A886AF-F2AB-4EA8-AB66-8B8080D5C86EQ28541351-86E15908-CA2D-4F8E-A23B-A2302C88FBD1Q28744173-C9777AEE-32C3-41B4-8F00-C7601B2474FDQ29248638-0C2C512C-BA26-4648-955D-092C6357C17FQ29616360-08D8A591-314C-401F-8E0E-E16D3090E073Q30560301-EAA28470-9213-492E-A2F1-F6554B1D2C79Q31121792-411C0A77-77D9-42E0-BCF0-A09F75E165A8Q32944410-8A8D0EEC-2A3A-4112-A1EF-3530236E1DEAQ33461138-C378FEFB-FF29-43F9-BEAE-81BEF1D89311Q33490826-D3C1C2F9-F369-48B3-B583-F5EA6B1C84C4Q33598619-33D1D951-4B38-45FC-8D7F-279998A171DAQ33625338-07CF6FA3-F973-497E-B102-D5D56AF700BCQ33634767-47D828CE-45C7-44BC-A5F4-CDFFDFB2A787Q33650801-D2270FC7-B453-4D03-8533-3D10ADB4A315Q33688593-C115E0FD-1F2A-4BD4-B268-66898F5C9D4AQ33697789-C5D2E64D-07F4-4714-BDF9-6560CD110E1AQ33707936-23C93FA9-617F-4F96-A8EA-6912BF817AD5Q33779205-D2457800-0FA2-4EA3-B7F4-740E16C92E6FQ33820241-6C1D4D5F-C2A9-4D7D-8914-0BF7A0F4C23DQ33829740-8620A2BA-00C8-479C-9E08-3DFCA1361AADQ33888977-4B19659B-8078-467F-93BD-7052A5134B03Q33995723-172B7D9E-7609-4A8D-983F-3B09F6172EEEQ34019641-D7912ECE-0E28-41DC-9606-B734C3A8E9CFQ34135442-5B253B15-7D69-4777-9402-ACCE007C7AC3Q34149920-A0067B63-F334-4706-B8BE-2C2D49BBF57AQ34205088-DCD63073-F15B-40F6-9499-6A314F275201Q34208986-31DAAC60-562D-4BAE-ADDB-DF2494460C73
P2860
Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@ast
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@en
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@nl
type
label
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@ast
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@en
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@nl
prefLabel
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@ast
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@en
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@nl
P1476
Epithelial-mesenchymal transit ...... drug resistance in the clinic.
@en
P2093
Alexander Pintzas
Angeliki Voulgari
P356
10.1016/J.BBCAN.2009.03.002
P407
P577
2009-03-21T00:00:00Z